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Objective: Adverse events (AEs) are health related events, reported by participants in clinical trials. We describe
AEs in the PACE trial of treatments for chronic fatigue syndrome (CFS) and baseline characteristics associated
with them.
Methods:AEswere recordedon three occasions over one year in 641 participants.We compared thenumbers and
nature of AEs between treatment arms of specialist medical care (SMC) alone, or SMC supplemented by adaptive
pacing therapy (APT), cognitive behaviour therapy (CBT) or graded exercise therapy (GET). We examined
associationswith baselinemeasures by binary logistic regression analyses, and compared the proportions of par-
ticipants who deteriorated by clinically important amounts.
Results: Serious adverse events and reactions were infrequent. Non-serious adverse events were common;
the median (quartiles) number was 4 (2, 8) per participant, with no signiﬁcant differences between treatments
(P= .47). A greater number of NSAEs were associated with recruitment centre, and baseline physical symptom
count, body mass index, and depressive disorder. Physical function deteriorated in 39 (25%) participants after
APT, 15 (9%) after CBT, 18 (11%) after GET, and 28 (18%) after SMC (P b .001), with no signiﬁcant differences
in worsening fatigue.
Conclusions: The numbers of adverse events did not differ signiﬁcantly between trial treatments, but physical de-
terioration occurred most often after APT. The reporting of non-serious adverse events may reﬂect the nature of
the illness rather than the effect of treatments. Differences between centres suggest that both standardisation of
ascertainment methods and training are important when collecting adverse event data.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Clinical trials frequently attribute health problems that arise during a
trial to the intervention. But, when health problems typically remit and
relapse, the attribution of all new health problems to the intervention
may be misleading. This study aims to explore this issue in patients
with chronic fatigue syndrome (CFS) who participated in a treatment
trial.
Adverse events reported by participants in clinical trials of
treatments may be considered to be clinically serious or not, and toal Medicine, St Bartholomew's
. This is an open access article underbe reactions to trial treatments or not. Few studies have examined
the associations and predictions of adverse events in trials. Several
trials have suggested a relationship between the reporting of adverse
events and negative affect; anxiety [1], depression [2] and neuroti-
cism [3]. Females and introverted participants of phase 1 medical
trials are more likely to report adverse events than males and extroverts
[4]. Physical symptoms at baseline predicted having a treatment
related adverse reaction in an antidepressant controlled trial [5]. As well
as this small literature regarding adverse events in trials, there are well
established associations between reporting physical symptoms, outside
of trials, and both mood disorders [6–10] and symptom burden [11].
Chronic fatigue syndrome (CFS) is characterised by long-standing
disabling fatigue and other symptoms that have no alternative medical
or psychiatric explanation [12]. Its nosological status and aetiology arethe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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such as irritable bowel syndrome and ﬁbromyalgia [14]. Treatments
recommended by theNational Institute of Healthcare and Clinical Excel-
lence (NICE) include cognitive behaviour therapy (CBT) and graded ex-
ercise therapy (GET) [15], but patient organisations have expressed
concern about their efﬁcacy and safety [16].
The PACE trial was a four arm randomised trial, which was de-
signed to compare three therapies each added to specialist medical
care (SMC) against SMC alone to determine both efﬁcacy and safety
[17]. The trial found that two therapies, CBT and GET, were more ef-
fective than adaptive pacing therapy (APT), when any of these ther-
apies were added to SMC, and were more effective than SMC alone
[17]. Whilst CBT and GET were designed to be rehabilitative, the
goal of APT was to optimise adaptation to the illness by planning
and pacing activities to avoid or reduce fatigue [17]. The trial mea-
sures of safety included systematic assessments of adverse events
(AEs), which occur uncommonly in trials of behavioural interventions
[18]. We have already reported that there were few serious adverse
events (SAEs) and even fewer serious adverse reactions (SARs), the
numbers of which did not differ signiﬁcantly across treatment arms
[17]. We have also reported various measures of deterioration, but not
whether there are any differences across treatment arms in the propor-
tions of participants who deteriorated in the two primary outcomes by
a clinically important amount [17]. This paper reports themore common-
ly reported non-serious adverse events (NSAEs), compares their frequen-
cy between treatment arms, and also identiﬁes baseline factors associated
with reporting larger numbers of NSAEs [17,19]. On the basis of the
previous literature, we hypothesised that NSAEs would be associated
with female sex, a larger number of physical symptoms at baseline,
and both depressive and anxiety disorders present at baseline. To
our knowledge there has been no previous study examining associations
of NSAEs in a trial of treatments for CFS or functional somatic syndromes.
Methods
Outline of the PACE trial
This report uses data from the PACE trial, relevant aspects of which
are described; more comprehensive accounts are available in the proto-
col [19], and the primary paper [17]. The PACE trial recruited 641
patients from secondary care clinics with a diagnosis of CFS, using
the Oxford criteria, which require six or more months of disabling
fatigue,with fatigue being the principal symptom, and no alternative, ex-
planatory diagnosis [20]. Participants were randomly allocated to one of
four treatment arms consisting of specialist medical care (SMC) alone or
SMC with one of APT, CBT or GET. Randomisation to the four treatment
arms was stratiﬁed by centre, co-morbid depressive disorder, and
different CFS and myalgic encephalomyelitis (ME) criteria [12,21].
Following randomisation, participants received up to 15 sessions of ther-
apy (if allocated to a therapy arm) and at least 3 sessions of SMC.
All consecutive new outpatients from six secondary care CFS clinics
in England and Scotland with a clinical diagnosis of CFS were clinically
assessed for eligibility and, if they agreed, were screened by a research
assistant (RA) for eligibility and consent for the trial. RAs were either
nurses or psychologists, who were independent of clinical staff, but
were not masked to treatment arms, this being impractical to achieve.
There was only one RA per centre, but over the trial period, RAs
left and were replaced in some centres. Recruitment commenced in
March 2005 and was completed by Nov 2008. Follow-up was up to
one year from randomisation.
Inclusion criteria were meeting the Oxford research diagnostic
criteria for CFS [20], a Chalder Fatigue Questionnaire binary score of 6
or more [22], a SF36 physical function sub-scale score of 65 or less
[23] and age at least 18 years old. Exclusion criteria were a signiﬁcant
risk of self-harm, being considered by the RA to be unable to participate
in the trial, participation in the PACE trial being inappropriate for clinicalneeds, and patients who had previously attended a PACE centre special-
ist fatigue clinic and received a course of PACE trial consistent treatment
[19].
The Structured Clinical Interview for DSM-IV was administered by
the RA, after appropriate training, and used to assess psychiatric comor-
bidity and psychiatric exclusions [24]. Further baseline information col-
lected included demographic details, current membership of a local or
national ME self-help group, and body mass index (BMI). Additional
self-report questionnaires included the Chronic Disease Self-Efﬁcacy
measure [25], physical symptoms (Patient Health Questionnaire;
PHQ-15) [26], Cognitive Behavioural Responses Questionnaire (CBRQ)
[27], Jenkins sleep scale of subjective sleep problems [28], and the Hos-
pital Anxiety and Depression Scale (HADS) [29]. Further assessments
consisted of the International (CDC) criteria for CFS [12], the London
criteria for myalgic encephalomyelitis [21] and the presence or absence
of ﬁbromyalgia [30].
Assessment of adverse events
Follow-up assessment interviews were conducted by the RA
at each centre on three occasions: 12, 24 and 52 weeks after
randomisation. At each of these time points the RA asked partici-
pants whether any new events or illnesses had taken place since
the last assessment including any events for which the participant
visited the GP or hospital department, or took medication [19]. AEs
were also recorded by treating specialist doctors and therapists if
spontaneously reported to them during the trial. An AE was deﬁned
as ‘any clinical change, disease or disorder experienced by the partic-
ipant during their participation in the trial, whether or not consid-
ered related to the use of treatments being studied in the trial’ [19].
We did not examine inter-rater reliability between RAs since we
did not foresee variability in these assessments.
AEs included: (a) any new co-morbid medical conditions reported, if
not previously reported at baseline, (b) any events for which the partic-
ipant consulted their GP or other medical advisor or took medication,
and (c) any other events that might have affected the health status of
the participant (e.g. increased work stress). Examples of NSAEs included
a cold (which had not caused serious disability), an eye infection, or
the experience of new pain (if not previously reported as a symptom of
the participant's CFS). If in doubt, the RA was encouraged to contact
the GP for both an update of all visits to the surgery since the last re-
search session and a list of any medications prescribed. The RA also
took note of any new events recorded in the clinic notes by the SMC
doctor at these sessions or reports thereof from the treating specialist
doctor or therapist.
Two consultant physicians and a consultant liaison psychiatrist, all
experienced in CFS, were appointed as independent scrutineers and
weremasked to the participants' allocated treatment group. They deter-
mined whether each AE was serious or non-serious. A serious adverse
event (SAE) was an event that resulted in one of the following out-
comes: a) death, b) threat to life (i.e., an immediate, not hypothetical,
risk of death at the time of the event), c) required hospitalisation except
for elective treatment of a pre-existing condition, d) increased severity
and persistent disability, deﬁned as: (i) severe, i.e. signiﬁcant deteriora-
tion in the participant's ability to carry out their important activities of
daily living (e.g. employed person no longer able to work, caregiver no
longer able to give care, ambulant participant becoming bed bound);
and (ii) symptom and disability persistent, i.e. of at least 4 weeks
continuous duration, e) any other important medical condition which,
though not included in the above, might require medical or surgical
intervention to prevent one of the outcomes listed, and f) any episode
of deliberate self-harm. For any AE established as serious, the
scrutineers were unmasked to treatment allocation to establish wheth-
er or not the event was a serious adverse reaction (SAR). A serious
adverse reaction was considered to be a reaction to one of the supple-
mentary therapies or a drug prescribed as part of SMC [19]. All those
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SARs.
A non-serious adverse event (NSAE) was any health event, which
was not categorised as an SAE or SAR. Each NSAE was ascribed to
the appropriate body system (gastroenterological, neurological, etc.) in-
dependently by two senior medical clinicians (one a consultant
infectious diseases physician, the other a consultant liaison psychia-
trist; both experienced in CFS), who were different from the inde-
pendent scrutineers. NSAEs attributed to CFS (i.e. considered to be
a symptom of CFS) were put into a separate category since there is
no consensually agreed body system for CFS, and because of speciﬁc
interest in these symptoms. Differences in clinicians' ratings were
resolved by discussion until consensus was reached. To summarise,
adverse events were any new health related event reported by the
participant in any context. These were independently judged as
serious adverse events, using an a priori guideline of seriousness,
and as serious adverse reactions if independently judged to be a
reaction to a trial intervention.Table 1
Non-serious adverse events (NSAEs) by treatment arm N (%)
Treatment
N
APT CBT GET SMC
159 161 160 160
Participants with NSAEs 152 (96) 143 (89) 149 (93) 149 (93)⁎
Number of NSAEs 949 848 992 977
Median (quartiles) NSAEs per
person-year
4 (2, 9) 4 (2, 7) 5 (2, 8) 4 (3, 8)#
N (%) N median number of NSAEs 81 (50) 78 (49) 90 (56) 79 (49)¶
APT = adaptive pacing therapy, CBT = cognitive behavioural therapy, GET = graded
exercise therapy, SMC = standardised specialist medical care.
⁎ X2 = 5.61, 3 df, P = .13.
# Kruskal–Wallis test of differences between treatment arms P = .47.
¶ X2 = 2.34, 3 df, P = b .51.Statistical analysis
Firstly, the frequencies of NSAEs reported by the participant were
compared between treatment arms and centres by chi squared tests.
Because there were individual differences between participants in
the duration of follow-up (depending on drop-outs) we calculated
the number of NSAEs per person year of follow-up, and compared
these across treatment arms. The distribution of NSAEs across trial
participants was non-normal, and attempts to normalise the
distribution by transformation were unsuccessful, so we used non-
parametric comparisons, such as Kruskal–Wallis tests. We then com-
pared the proportions of participants with NSAEs attributed to dif-
ferent body systems across treatment arms, with a chi squared test.
A Poisson regression model was attempted with the frequency of
NSAEs per participant, but this did not provide an adequate ﬁt to the
data due to the variance exceeding the mean (extra-Poisson variation);
a negative binomial model was uninformative. Instead we used a
median split (4/5) of the numbers of NSAEs, determined by analysis of
the frequency of NSAEs per participant, as well as CFS related NSAEs
per participant (0/1) in order to examine univariate associations with
baseline characteristics. Therewere no informative independent studies
of non-serious adverse events to guide us.
Secondly, univariate analyses of associations between NSAEs and
other variables were conducted, with continuous variables transformed
when not normally distributed. The chi-squared test was used for cate-
gorical variables. The t-test was used for continuous normally distributed
variables.
Thirdly, all associated univariate variables, signiﬁcant at P ≤ .1,
were entered into a multivariate binary logistic regression model
for all NSAEs, followed by a separate regression analysis for NSAEs
attributed to CFS. Age, sex and treatment arm were also entered
into all models. We also modelled those with one or more NSAEs
versus those without any, using a logistic regression analysis to
establish characteristic differences between these two groups of
patients.
In order to provide further checks on the relatedness of adverse
events in general to trial treatments, we compared both serious adverse
events and reactions, and the numbers of participants in each treatment
group who reported being “much worse” or “very much worse” in
their overall health at 52 weeks after randomisation [31]. We also
compared the numbers of participants in each treatment arm who
had deteriorated by more than a clinically important difference (at
least 2 points on the fatigue questionnaire and/or at least 8 points on
physical function, which represented 0.5 of a standard deviation of
baseline outcome measures) between randomisation and 52 weeks
later [17]. We then examined the number of NSAEs in those who haddeteriorated by either of the latter measures. We analysed the data
using SPSS v18 and v22.
As a post-hoc analysis, in order to better understand the differences
inNSAE counts between centres,we stratiﬁed centres into three groups:
low (3 centres), medium (2 centres) and high (1 centre) numbers of
NSAEs per participant. Using these strata,we undertook a oneway anal-
ysis of variance (ANOVA) of those continuous variables that showed sta-
tistically signiﬁcant differences by NSAE count on univariate analyses.
We examined linear trends across centre strata.
Results
Most (77%) participants were female, with only 7% from ethnic minorities. The mean
(SD) age of participants was 38 (12) years. Approximately half of participants were edu-
cated to A-level or degree level standard (Appendix A, Table A). One participantwithdrew
their consent after participation, leaving 640 in the analysis.
Themedian (quartiles) number of reportedNSAEs per participant per annumwas4 (2,
8), with no signiﬁcant difference between treatment arms (Kruskal–Wallis test P= .47)
(Table 1). This median was used to divide the sample into those with lower (≤4) and
higher (≥5) numbers of NSAEs for the purpose of binary logistic regression analyses. The
number (%) of trial arm participants with more than the median number of NSAEs varied
from78 (49%), in those allocated to CBT, to 90 (56%) in those allocated toGET (X2= 2.34, 3
df, P b .51) (Table 1). Fig. 1 shows that thedistributions of NSAE counts had similar patterns
across the treatment groups, butwithmore participants having noNSAEs in the CBT group
(post-hoc comparison of CBT participants versus all others combined: 6% versus 11%, chi-
squared = 4.65, 1 df, P= .03).
A highly statistically signiﬁcant difference in the reporting of NSAEs between trial cen-
tres was found (P b .001). This varied from a median of 4 in one centre to 10 in another
centre (Appendix A, Table B).
Types of NSAE
NSAEs affecting eyes, ears, nose and throat were reported by 54% of participants, with
46% of participants reporting NSAEs attributed to CFS (Table 2). Smaller numbers of partic-
ipants had gastrointestinal, psychiatric/psychological and musculoskeletal NSAEs
(Table 2). Chi squared tests showed no statistically signiﬁcant differences in any of the
comparisons across the four treatment arms (Table 2).
Univariate associations
There were no signiﬁcant associations of NSAEs with socio-demographic characteris-
tics (Appendix A, Table A). In contrast, there were signiﬁcant associations between in-
creased reporting of NSAEs and several baseline variables: the numbers of both physical
symptoms in general and symptoms of CFS, higher BMI, worse physical function, avoid-
ance due to embarrassment, more fatigue, and HADS depression (Table 3). The mean
(standard deviation) BMI was 25.5 (4.97) for all 640 participants. Some 123 (19%) partic-
ipants weremorbidly obese (BMI≥30). Signiﬁcant associations were also found between
reporting more NSAEs and having any psychiatric disorder, particularly depressive disor-
der, dysthymia, andmajor depressive disorder (Table 4). Therewere no signiﬁcant associ-
ations with anxiety disorders.
Multivariable binary logistic regression of NSAEs
When modelling all NSAEs, using a median split of 4 or less versus 5 or more, centre
effects dominated the models, so we remodelled both with and without centre. Without
centre, a larger number of NSAEs were associated with baseline CFS symptom count
(odds ratio (OR, 95% CI) 1.12 (1.01, 1.24), P = .03), physical symptom count 1.04 (0.99,
1.08), P = .09, baseline current depressive disorder 1.47 (1.04, 2.07), P = .03, and log
Fig. 1. Histograms of non-serious adverse events by treatment arm.
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lost from the model, as was the number of physical symptoms, but CFS symptoms
(P b .001) and BMI (P= .035)were retained. Therewas no signiﬁcant interaction between
centre and treatment arm when this interaction term was entered into the model, indicat-
ing no differential effects of centre on treatments.
The one factor associated with one or more versus no NSAEs was CFS symptom
count (1.17 (0.99, 1.38), P = .065). Adding centre to the model retained CFS symptom
count (P= .01) and added treatment arm, but only at a P value of .10.Multivariable binary logistic regression of CFS related NSAEs
CFS related NSAEs were associated with baseline depressive disorder (1.81 (1.29,
2.53), P= .001) andbaseline CFS symptomcount (1.13 (1.03, 1.24), P= .008). Adding cen-
tre replaced baseline depressive disorder with baselinemajor depressive episode (P= .03)
and added physical symptom count (P= .09) as well as CFS symptom count (P= .006).Post-hoc exploration of centre effects on NSAE count
Seven of ten variables measured at baseline were signiﬁcantly correlated in a linear
trendwith centres stratiﬁedbyNSAE count in theANOVA (AppendixA, Table B).However,
the variation betweenmean scores per centre varied little, with themost signiﬁcant differ-
ent variables of Chalder fatigue, SF36, and PHQ-15 varying by 2, 6 and 2.8 points respec-
tively. There were no signiﬁcant correlations for age, sex, duration of illness, and
embarrassment scores.Deterioration by other measures
Table 5 shows that there were no statistically signiﬁcant differences between
treatment arms in those who had an SAE, SAR, or in those who had deteriorated either
by CGI score (of either “much” or “very much worse”). This was also the case for fa-
tigue alone and fatigue and disability combined. Similarly, there were no signiﬁcant
differences across treatment arms between the median number of NSAEs in those
who had deteriorated as measured by the global impression change score (P = .97)
and those reporting deterioration in both primary outcomes of fatigue and physical
disability (P = .16) between treatment groups. However, there was a signiﬁcant dif-
ference in deterioration of physical function, across treatment arms, with a quarter of
those who received APT deteriorating in this way, compared to 18% after SMC, and
11% and 9% after GET or CBT respectively.
Discussion
Therewere no important differences between treatment arms in any
of the adverse events, however they were measured or classiﬁed. Most
importantly there was no evidence of more frequent adverse events
after either CBT or GET. The factors associated with a higher number
of NSAEs were the centre where the participant was seen, followed by
the number of physical symptoms at baseline, having a depressive epi-
sode, and higher body mass index. Those variables associated with CFS
Table 4
Association of baseline diagnoses with number of NSAEs below and above median N (%)
NSAE ≤4 NSAE N4 X2 P
Total 313 49% 327 51%
London ME case
Met (329) 177 56 152 46 6.49 .011
Not met (311) 136 44 175 54
All psychiatric diagnoses
Present (299) 128 41 171 52 8.35 .004
None (341) 185 59 156 48
All depressive disorders
Present (213) 85 27 128 39 10.35 .001
None (427) 228 73 199 61
Major depressive disorder
Present (112) 44 14 68 21 5.03 .025
None (528) 269 86 259 79
Minor depressive disorder
Present (67) 28 9 39 12 1.52 .220
None (573) 285 91 288 88
Dysthymic disorder
Present (71) 24 8 47 14 7.29 .007
None (569) 289 92 280 86
All anxiety disorders
Present (202) 92 29 110 34 1.33 .250
None (438) 221 71 217 66
Generalised anxiety disorder
Present (132) 56 18 76 23 2.80 .094
None (508) 257 82 251 77
Fibromyalgia
Present (138) 69 22 69 21 0.07 .79
None (501) 244 78 257 79
SAEs or SARs during follow-up
Present (51) 20 6 31 9 2.08 .15
None (589) 293 94 296 91
All depressive disorders included major and minor depressive disorders and dysthymia.
All anxiety disorders included generalised anxiety disorder, panic disorders, phobias and
post-traumatic stress disorders. SAEs + SARs = number of participants with one or
more serious adverse events or reactions.
Table 2
Numbers (%) of participantswith one ormore non-serious adverse events by body system
Body system Trial arm % X2 P
APT
(159)
CBT
(161)
GET
(160)
SMC
(160)
Eyes & ENT 91 (57) 87 (54) 81 (51) 87 (54) 54 1.41 .70
CFS/ME/PVFS 73 (46) 66 (41) 79 (49) 76 (48) 46 2.50 .47
Gastrointestinal 59 (37) 57 (35) 53 (33) 67 (42) 37 2.84 .42
Psychol/psychiatric 57 (36) 56 (35) 47 (29) 52 (33) 33 1.78 .62
Musculoskeletal 56 (35) 47 (29) 53 (33) 41 (26) 31 4.07 .25
Obs/gynae/urinary 40 (25) 34 (21) 34 (21) 33 (21) 22 1.22 .75
Respiratory 34 (21) 30 (19) 36 (23) 49 (31) 22 7.15 .067
Dermatological 33 (21) 21 (13) 30 (19) 35 (22) 19 4.91 .18
Neurological 26 (16) 26 (16) 31 (19) 39 (24) 19 4.58 .21
Stressful events 18 (11) 17 (11) 26 (16) 19 (12) 13 2.87 .41
Cardiovascular 8 (5) 11 (17) 8 (5) 11 (7) 6 0.97 .81
Nutrient & blood 5 (3) 2 (1) 8 (5) 3 (2) 3 4.83 .18
Allergies 2 (1) 6 (4) 6 (4) 4 (3) 3 2.47 .48
Endocrine 8 (5) 4 (2) 1 (1) 3 (2) 3 6.74 .081
Miscellaneous 4 (3) 5 (3) 3 (2) 8 (5) 3 2.88 .41
The table gives the number (%) of participants having one or more non-serious adverse
events during their participation in the trial, separated into individual body systems.
APT = adaptive pacing therapy, CBT = cognitive behavioural therapy, GET = graded ex-
ercise therapy, SMC = standardised specialist medical care. ENT = ear, nose and throat.
CFS = chronic fatigue syndrome, ME = myalgic encephalomyelitis, PVFS = post-viral
fatigue syndrome.
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sode. The common baseline associations in both models were centre,
depressive disorder and physical symptom count. Those who received
APT were most likely to deteriorate by a clinically important amount
in physical function, with those in receipt of CBT being least likely to
deteriorate.
The substantial variation in the frequency of the reporting of
NSAEs between centres is our most unexpected ﬁnding, although
variation between centres is not uncommon in multi-centre trials
[32], and this did not inﬂuence treatment response [17]. We found
statistically signiﬁcant linear associations between centres stratiﬁedTable 3
Univariate comparisons of baseline variables in those below & above median number of
non-serious adverse events (NSAEs)
Variable NSAE ≤4
(N 313)
NSAE N4
(N 327)
t P
Mean SD Mean SD
CFS symptom count 4.4 1.8 4.9 1.8 3.87 b .001
PHQ-15 13.5 4.3 14.8 4.8 3.63 b .001
BMI 25.0 4.8 25.9 5.1 2.40 .02
SF36 PF 39.6 15.2 36.5 16.2 2.48 .01
CBRQ embarrassment 11.6 5.5 12.6 5.5 2.33 .02
Fatigue 27.8 3.7 28.5 3.8 2.15 .03
HADS depression 8.0 3.6 8.6 3.9 2.14 .03
HADS anxiety 7.7 4.2 8.3 4.3 1.80 .07
CBRQ all or nothing 13.6 3.8 14.1 3.8 1.57 .12
CBRQ catastrophising 7.6 3.4 8.0 3.3 1.54 .12
WSAS 26.9 6.3 27.6 6.3 1.39 .16
Jenkins sleep 11.9 4.8 12.4 4.8 1.23 .22
Self-efﬁcacy 4.8 1.5 4.7 1.6 0.86 .39
CBRQ behaviour avoidance 18.8 4.9 19.2 5.2 0.56 .58
CBRQ symptom focusing 12.8 4.9 13.0 5.0 0.51 .61
CBRQ fear avoidance 15.2 4.0 15.1 3.9 0.19 .85
CBRQ damage 11.0 3.4 11.0 3.3 0.025 .98
CFS = chronic fatigue syndrome, PHQ = Patient Health Questionnaire, BMI = body mass
index, SF36 PF = short form 36 item physical function, HADS = Hospital Anxiety
Depression Scale, CBRQ = Cognitive Behavioural Responses Questionnaire, WSAS = Work
and Social Adjustment Scale.by NSAE counts and a number of baseline variables, but the differ-
ences between centres were small, and nothing like the size of differ-
ences in NSAE frequency across centres. This suggests that the large
differences in NSAE numbers between centres are unlikely to be related
to the small differences found between centres in baseline factors. Al-
though the research assessments across centres were standardised
and training was provided at the start of the trial, it might be that the
differenceswere due to differentmethods of ascertainment. This appar-
ent variation in recording NSAEs, despite a standard protocol for doing
so, has important implications for recording adverse events in future
trials.
Having more symptoms at baseline, particularly those associated
with CFS, predicted subsequent NSAEs in general and also NSAEs at-
tributed to CFS. This replicates previous work [5]. Higher symptom
counts are associated with somatoform disorders in secondary care
[33], and may reﬂect a general tendency to report symptoms,
which is associated with, but also independent of, mood disorders
[34]. The speciﬁcity of CFS symptoms at baseline being associated
with NSAEs attributed to CFS suggests a speciﬁc tendency to report
these symptoms, rather than a generic inﬂuence of reporting any
symptom. It may also reﬂect the relapsing and remitting nature of
CFS.
Our ﬁnding that a diagnosis of a depressive disorder at baseline pre-
dicted increased reporting of NSAEs is consistent with previous studies
that found negative affect to be associated with NSAEs speciﬁcally [1,3],
and somatic symptoms in general [6–10,35]. This association remained
signiﬁcant for both NSAEs as a whole and for CFS attributed NSAEs in
one regression model. Unlike some previous studies, we did not ﬁnd
an association with anxiety, either with the HADS score or through
Table 5
Serious adverse events/reactions and deterioration by 52 weeks (N %)
Treatment (N) APT
159
CBT
161
GET
160
SMC
160
Chi-sq P
Serious adverse events 15 (9) 7 (4) 13 (8) 7 (4) 5.3 .15
Serious adverse reactions 2 (1) 3 (2) 2 (1) 2 (1) 0.3 .96
Physical function worse 39 (25) 15 (9) 18 (11) 28 (18) 17.2 .0007
Fatigue worse 21 (13) 14 (9) 11 (7) 22 (14) 5.8 .12
Function & fatigue worse 11 (7) 4 (2) 5 (3) 8 (5) 4.6 .21
Median (quartile) NSAEs in those worse 8 (4, 11) 3 (2, 5) 7 (4, 14) 4 (3, 12) .16
CGI worse 10 (6) 9 (6) 10 (6) 14 (9) 1.5 .69
Median (quartile) NSAEs in those worse by CGI 6 (4, 8) 8 (2, 11) 6 (2, 17) 4 (3, 14) .97
Physical functionworse = SF36 sub-scale score 8 ormore points' deterioration; fatigueworse = Chalder fatigue questionnaire score 2 ormore points' deterioration, CGI = Clinical Glob-
al Impression change = “much” or “verymuch”worse. APT = adaptive pacing therapy, CBT = cognitive behavioural therapy, GET = graded exercise therapy, SMC = standardised spe-
cialist medical care.
25D. Dougall et al. / Journal of Psychosomatic Research 77 (2014) 20–26the SCID interview. One other trial failed to ﬁnd an association between
anxiety and adverse events [5].
We found that a higher BMI was associated with NSAEs in gener-
al. This observation may have several explanations; obese people
generally report more of both physical and mental health related
problems [36], and our sample included 123 (19%) participants
who were morbidly obese. We were not able to replicate a previous
research ﬁnding that female participants are more likely to report
adverse events [4].
The strengths of this paper are that it used data from a large trial
from multiple centres. The assessment of NSAEs on three occasions
improved sensitivity. The limitations include the difference in frequen-
cy of NSAE reporting between centres, implying variation in ascertain-
ment, although controlling for centre did not signiﬁcantly affect our
main ﬁndings. We only measured deterioration using self-ratings,
rather than objectivemeasures.Wewere unable tomodel the full distri-
bution of NSAEs, which may have limited the power of our regression
models.Table A
Sociodemographic characteristics: univariate comparisons
Number of reported adverse events NSAE ≤4 NSAE N4
N % N % X2 P
Total (N) 313 49 327 51
Gender (1 df)
Female (495) 237 76 258 79 0.92 .34
Male (145) 76 24 69 21
Ethnicity (1 df)
Other (40) 20 6 20 6 0.038 .84
White (595) 288 94 307 94
Educational level (5 df)
Minimal (24) 17 5 7 2 6.51 .26
GCSE/equivalent (110) 47 15 63 19
A level/equivalent (127) 64 20 63 19
Degree (198) 96 31 102 33Conclusions
We found that there were no important differences in any of the
adverse events between treatment arms, and no excess associated
with either CBT or GET. Clinically important deterioration occurred
least often after CBT and GET; APT may be associated with more fre-
quent deterioration in physical functioning. We also noted that
the reporting of non-serious adverse events in a clinical trial of
treatment for CFS varied by recruitment centre, perhaps related to
the method of ascertainment. This important ﬁnding has implica-
tions for the design of future trials. Research assessors need clear
manualised guidance on the various deﬁnitions of adverse events,
and speciﬁc training and supervision in order to implement them.
We also found that baseline symptom count, having a depressive dis-
order and BMI were signiﬁcantly associated with a greater number of
NSAEs, independently of the treatment arms. This has both research
and clinical implications for clinicians running trials, particularly
those including patients with CFS. Adverse events in trials may
more accurately reﬂect ﬂuctuations in a condition, rather than reac-
tions to interventions.Postgraduate (114) 57 18 57 17
Other (67) 32 10 35 11
ME group member (3 df)
Local only (33) 16 5 17 5 4.3 .23
National only (54) 20 7 34 10
Both (18) 11 4 7
No group (535) 266 50 269 82
Mean SD Mean SD t P
Age at randomisation (years) 38.4 11.6 38.3 12.1 0.014 .79Conﬂicts of interests
PDW has done voluntary and paid consultancy work for the United
Kingdom government and a reinsurance company. TC has received roy-
alties from Sheldon Press and Constable and Robinson.MS has done vol-
untary and paid consultancywork for the United Kingdom government,
has done consultancy work for an insurance company, and has receivedroyalties from Oxford University Press. DD, ALJ, KG and BA declare that
they have no conﬂicts of interests.
Funding
Funding for the PACE trial was provided by the Medical Research
Council, the Department of Health for England, the Scottish Chief Scien-
tist Ofﬁce (G0200434), and the Department for Work and Pensions. DD
was funded by the East London FoundationNHSTrust. TC acknowledges
support from theNIHR Biomedical Research Centre forMental Health at
the South London and Maudsley NHS Foundation Trust and Institute of
Psychiatry, Kings College London.
Acknowledgments
The authors acknowledge the help and advice of Hannah Baber (trial
manager). The PACE Trial Management Group consisted of the authors
of this paper, excluding DD, plus (in alphabetical order): H. Baber, J.
Bavinton, M. Burgess, L.V. Clark, D.L. Cox, J.C. DeCesare, E. Feldman, P.
McCrone, G. Murphy, M. Murphy, H. O'Dowd, T. Peto, L. Potts, R.
Walwyn, and D. Wilks.
Appendix A
Table B
Variation of non-serious adverse events and baseline variables by centre (N %)
A B C D E F P value
Median (quartiles) NSAE count 3 (1, 4) 3 (2, 5) 4 (2, 6) 7 (4, 10) 8 (4, 13) 10 (6, 15) b .001*
NSAE ≤4 (313) 86 (78) 74 (69) 78 (58%) 38 (34) 32 (29) 5 (8)
NSAE N4 (327) 24 (22) 34 (31) 57 (42%) 75 (66) 79 (71) 58 (92) b .0001#
Chalder fatigue 28.5 (3.6)¶ 28.1 (3.4) 27.2 (4.1) 28.8 (3.6) 28.0 (3.9) 29.2 (3.5) .005$
SF36 PF 39 (16) 40 (16) 41 (13) 36 (16) 35 (16) 37 (16) .006
CFS symptoms 5.0 (1.7) 4.6 (1.7) 4.3 (1.8) 4.6 (1.8) 4.7 (1.8) 5.4 (1.8) .01
HADS anxiety 7.7 (4.4) 7.3 (3.7) 8.1 (4.6) 7.9 (4.2) 8.4 (4.2) 9.3 (3.8) .008
HADS depression 8.3 (3.5) 7.6 (3.2) 8.2 (3.8) 8.4 (4.0) 8.4 (4.0) 9.4 (4.2) .02
PHQ-15 14.4 (3.9) 13.8 (4.3) 12.9 (4.4) 14.2 (4.2) 14.8 (5.2) 15.7 (5.5) b .001
BMI 25.2 (4.7) 27.0 (5.5) 24.0 (5.5) 25.5 (4.7) 25.1 (5.0) 27.2 (5.3) .04
*Kruskal–Wallis. #χ2 (5df) = 129.4, P b .0001. NSAE = non-serious adverse events. SF36PF = SF36physical function sub-scale score. HADS = Hospital AnxietyDepression Scale. PHQ-
15 = Patient Health Questionnaire. ¶Last seven lines showmeans (SD). $The comparisons were by one way ANOVA across the centre strata of low, medium and high NSAE counts, with
linear test for trend.
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